PD Research News · Curated · Newest First
Gossip Hill
Field notes, the long arc, and what's on the wires.
Two trials, two continents: BlueRock (embryonic-derived) and Kyoto/Sumitomo (iPSC) cell transplants show dopamine production and motor improvement in Nature.
Read
Health panel approves coverage for iPS cell-derived Parkinson’s disease treatment.
Read
2026 FDA-expected decision: Tavapadon (AbbVie) for Parkinson Disease.
Read
Nicotinamide Riboside fails in Parkinson's: the NOPARK trial (Tzoulis, Haukeland/Bergen) missed its primary endpoint. Disclosed on Niagen Bioscience's FQ4 2025 earnings call — manuscript not yet submitted, pre-peer-review. Sponsor reframing NR toward prevention.
The Dopamine Debate: cardiologist Dr. Jonathan Sackner-Bernstein argues PD may stem from too much dopamine, not too little — challenged by Dr. Kit Wu.
Listen
Bas Bloem on Prof. Rascol's PREMANDYSK trial: early amantadine cut peak-dose dyskinesia by half at 18 months in Movement Disorders.
Listen
ITOCHU announces basic agreement on development and licensing of an automated iPS cell culture kit.
Read
Disease-modifying Parkinson's therapy ENERGI-F705PD found safe in volunteers.
Read
Sumitomo Pharma seeks approval for the world's first Parkinson's iPS cell therapy (Shinya Yamanaka).
Read
Dr. Karunapuzha on how to take levodopa for Parkinson's.
Listen
Mitochondria Unlocked: cellular-level health with Rob Fried, CEO @ Chromadex.
Listen
Stem cells, cell replacement, and Parkinson's — a conversation with Dr. Roger Barker.
Listen
Movers and Shakers, a podcast about life with Parkinson's — episode on cell therapy.
Listen
Key Parkinson's trial delayed due to a feud between a Georgetown University scientist and the Michael J. Fox Foundation.
Read